Global Gallium-68 Ga-68 Market Insights, Size, and Forecast By Formulation (Injectable, Lyophilized, Liquid), By Distribution Channel (Direct Sales, Distributors, Online Sales), By End Use (Hospitals, Diagnostic Centers, Research Institutions), By Application (Positron Emission Tomography, Radiopharmaceuticals, Research and Development), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Gallium-68 Ga-68 Market is projected to grow from USD 0.85 Billion in 2025 to USD 2.95 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. This market encompasses the production, distribution, and application of Gallium-68, a radioactive isotope primarily used in positron emission tomography (PET) imaging. Ga-68 is typically eluted from a generator system, making it readily available for on site preparation of radiopharmaceuticals. The market is propelled by the increasing global incidence of cancer, particularly neuroendocrine tumors (NETs) and prostate cancer, for which Ga-68 labeled somatostatin receptor analogues and PSMA ligands offer superior diagnostic accuracy compared to traditional imaging modalities. Advancements in radiopharmaceutical research and development, coupled with growing awareness among healthcare professionals regarding the benefits of Ga-68 PET imaging, further fuel market expansion. However, market growth faces restraints such as the high cost associated with Ga-68 generators and imaging procedures, as well as the limited availability of trained personnel and specialized infrastructure required for its use. Stringent regulatory approval processes for new radiopharmaceuticals also pose a challenge, potentially delaying market entry for innovative solutions.
Global Gallium-68 Ga-68 Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
A significant trend shaping the Gallium-68 Ga-68 market is the continuous innovation in radioligand therapy (RLT) using Ga-68 for patient selection and monitoring, paving the way for theranostic applications. This synergy between diagnosis and therapy represents a substantial growth opportunity, as clinicians increasingly seek personalized medicine approaches for cancer treatment. Furthermore, the expansion of clinical trials exploring new Ga-68 labeled tracers for various oncological and neurological indications is expected to broaden the market's scope. The market's leading segment is Positron Emission Tomography, demonstrating the widespread adoption and critical role of Ga-68 in diagnostic imaging. Opportunities also lie in developing more cost-effective production methods for Ga-68 generators and expanding their reach to emerging economies where access to advanced diagnostic tools is still developing. Additionally, the development of automated synthesis modules for Ga-68 radiopharmaceuticals could streamline preparation processes and enhance efficiency, further driving adoption.
North America stands as the dominant region in the global Gallium-68 Ga-68 market, driven by a well-established healthcare infrastructure, high adoption rates of advanced medical technologies, significant research and development investments, and a favorable reimbursement landscape for PET imaging procedures. The presence of key market players and a robust network of academic and research institutions also contribute to its leading position. Conversely, Asia Pacific is projected to be the fastest-growing region, primarily due to increasing healthcare expenditure, a rapidly expanding patient pool, improving access to advanced diagnostic imaging, and growing awareness of nuclear medicine applications. Government initiatives to enhance healthcare infrastructure and rising disposable incomes in countries across the region are also contributing to this accelerated growth. Key players in this competitive landscape include Iochem, Novartis, Curium, Elekta, GMP Laboratories, RadioMedix, NMS Healthcare, ITG Isotope Technologies Garching, General Electric, and Advanced Accelerator Applications. These companies are strategically focusing on research and development to introduce novel Ga-68 radiopharmaceuticals, forge partnerships, expand their global distribution networks, and acquire smaller innovative companies to solidify their market presence and capitalize on emerging opportunities.
Quick Stats
Market Size (2025):
USD 0.85 BillionProjected Market Size (2035):
USD 2.95 BillionLeading Segment:
Positron Emission Tomography (62.8% Share)Dominant Region (2025):
North America (38.2% Share)CAGR (2026-2035):
14.2%
Global Gallium-68 Ga-68 Market Emerging Trends and Insights
Theranostics Expansion Driving Ga68 Adoption
Theranostics, merging therapeutics and diagnostics, is rapidly expanding, and Ga68 plays a pivotal role in this growth. Its unique properties make it an ideal diagnostic radiotracer in various theranostic applications, particularly for precise tumor localization and characterization before and during radionuclide therapy. As more radioligand therapies emerge, the demand for companion diagnostics like Ga68 imaging increases proportionally. This synergy between targeted therapies and Ga68 diagnostics enhances treatment efficacy and patient selection. The growing pipeline of Ga68 based radiopharmaceuticals and their increasing clinical use across oncology is a primary driver for Ga68 adoption. The shift towards personalized medicine further amplifies this trend, with Ga68 facilitating tailored treatment strategies.
Automated Synthesis Innovations Reshaping Ga68 Supply
Automated synthesis innovations are revolutionizing Ga68 supply by streamlining production and enhancing accessibility. Traditionally, Ga68 generator manufacturing was a labor intensive, multi step process with potential for inconsistencies. New automated platforms integrate radiopharmaceutical synthesis, purification, and dispensing into compact, robotic systems. This reduces human error, improves batch to batch reproducibility, and shortens production cycles significantly. By automating complex chemistry, these innovations enable more efficient utilization of cyclotron produced Germanium 68, the parent radionuclide. The trend allows smaller radiopharmacies and hospitals to produce Ga68 tracers on demand, decentralized from large manufacturing centers. This expands the geographic reach of Ga68 PET imaging, making advanced diagnostics more readily available globally and ultimately reshaping the entire Ga68 supply chain towards greater efficiency and responsiveness.
Decentralized Production Boosting Ga68 Accessibility
Decentralized production is significantly improving Ga68 accessibility worldwide. Traditionally, Ga68 generators were produced in a few central locations, leading to complex logistics, lengthy delivery times, and high shipping costs, especially for smaller imaging centers or those in remote areas. The emergence of smaller scale, regionally distributed Ga68 production facilities addresses these challenges. These localized production hubs enable faster delivery, reduce transportation expenses, and minimize the risk of supply chain disruptions. By bringing production closer to end users, more hospitals and clinics can readily access Ga68 for PET imaging. This localized approach is crucial for expanding Ga68 utilization beyond major academic centers, making this vital diagnostic tool available to a broader patient population globally.
What are the Key Drivers Shaping the Global Gallium-68 Ga-68 Market
Escalating Demand for Advanced PET Imaging in Oncology
Oncology is experiencing a surge in the need for sophisticated diagnostic tools, particularly advanced PET imaging. Gallium-68 Ga-68 based radiopharmaceuticals offer unparalleled precision in detecting and staging various cancers, including neuroendocrine tumors and prostate cancer. Clinicians are increasingly relying on Ga-68 PET scans for more accurate disease characterization, treatment planning, and monitoring therapeutic response. This heightened demand stems from improved patient outcomes associated with earlier and more precise cancer detection. As understanding of cancer biology deepens, the imperative for highly specific and sensitive imaging agents like Ga-68 grows, driving its adoption across oncology centers globally to enhance diagnostic capabilities and personalized patient management.
Expansion of Radiopharmaceutical Production and Distribution Infrastructure
The growing demand for Gallium-68 radiopharmaceuticals necessitates a substantial expansion of production and distribution capabilities. This driver involves significant investment in new cyclotron facilities and specialized hot cells for Ga-68 generator production. Enhancements to logistical networks are crucial, including the development of dedicated transportation routes and improved cold chain management to ensure the timely and safe delivery of these short-lived diagnostic agents to hospitals and imaging centers worldwide. This infrastructure growth is also driven by the need to standardize manufacturing processes and adhere to stringent regulatory requirements across different regions, ultimately aiming to increase accessibility and reduce delivery times for patients requiring PET scans.
Favorable Regulatory Approvals and Reimbursement Policies for Ga-68 Tracers
Favorable regulatory approvals and reimbursement policies for Ga-68 tracers are a significant driver in the global Ga-68 market. When regulatory bodies like the FDA or EMA approve new Ga-68 based radiopharmaceuticals, it allows these innovative diagnostic tools to reach patients and be utilized by healthcare providers. This governmental endorsement validates the safety and efficacy of the tracers, encouraging their adoption. Simultaneously, robust reimbursement policies from insurance providers are crucial. If healthcare systems and private insurers cover the cost of these scans, it significantly reduces the financial burden on patients and clinics, making Ga-68 imaging more accessible and affordable. This accessibility, driven by both approval and reimbursement, directly translates into increased demand and wider utilization of Ga-68 tracers, fueling the market's expansion and fostering greater investment in research and development for new applications.
Global Gallium-68 Ga-68 Market Restraints
Regulatory Hurdles and Reimbursement Challenges in Ga-68 Radiopharmaceuticals
Regulatory hurdles and reimbursement challenges significantly impede the growth of Ga-68 radiopharmaceuticals. The stringent approval processes by various health authorities worldwide for new Ga-68 based diagnostics are protracted and resource intensive. This extended pathway from research to clinical availability delays patient access to innovative imaging agents. Furthermore, obtaining adequate reimbursement from healthcare payers for these advanced radiopharmaceuticals remains a substantial barrier. Insufficient or inconsistent coverage across different regions makes it challenging for providers to justify the investment in Ga-68 generators and imaging equipment. The lack of clear reimbursement codes or established pathways often results in delayed payments or outright denials, impacting the financial viability of adopting these crucial diagnostic tools. These combined factors restrict the broader adoption and market penetration of Ga-68 radiopharmaceuticals despite their clinical utility.
Supply Chain Disruptions and Manufacturing Bottlenecks for Ga-68 Generators
The global Gallium-68 market faces a significant restraint from widespread supply chain disruptions and manufacturing bottlenecks for Ga-68 generators. These disruptions stem from various factors including geopolitical tensions, raw material shortages particularly enriched Germanium-68, and logistical challenges in transporting specialized equipment and precursors. Production facilities for generators also contend with capacity limitations and the need for highly specialized manufacturing processes and quality control. This confluence of issues leads to delays in generator availability, increased lead times, and potential price volatility. Ultimately, the inconsistent and limited supply of Ga-68 generators hinders the broader adoption of Ga-68 radiopharmaceuticals, impacting patient access to crucial diagnostic imaging and restraining the market's growth potential.
Global Gallium-68 Ga-68 Market Opportunities
Expanding Precision Oncology Diagnostics with Ga-68 Radiopharmaceuticals
The opportunity involves expanding the application of Gallium-68 radiopharmaceuticals to enhance precision oncology diagnostics globally. These advanced agents enable highly accurate molecular imaging for various cancers, allowing clinicians to precisely identify tumor locations and assess biological activity. This capability is pivotal for tailoring treatment strategies, monitoring patient response to therapies, and detecting disease recurrence at earlier stages.
Ga-68 radiopharmaceuticals, such as Ga-68 PSMA for prostate cancer and Ga-68 DOTA compounds for neuroendocrine tumors, offer superior diagnostic resolution. As cancer treatment evolves towards personalized medicine, the demand for these precise diagnostic tools will accelerate. Developing new Ga-68 tracers targeting a broader spectrum of cancers presents a substantial growth avenue. The ability of Ga-68 PET imaging to guide therapeutic decisions makes it indispensable for advancing precision oncology, driving significant investment and adoption across healthcare systems worldwide.
Leveraging Ga-68 Generator Technology for Decentralized PET Imaging Access
The opportunity lies in Ga-68 generators enabling widespread access to advanced PET imaging, particularly in areas lacking centralized cyclotron facilities. These generators offer a convenient, on site source of Ga-68, overcoming logistical hurdles associated with short lived isotopes. This technology empowers smaller hospitals and clinics, especially in rapidly expanding healthcare markets, to offer sophisticated diagnostics for oncology and neuroendocrine tumor detection directly to patients. By decentralizing radioisotope production, healthcare providers can significantly reduce patient travel times, improve scan scheduling flexibility, and lower overall operational costs for PET centers. This expands the geographic footprint of PET imaging, reaching underserved populations and accelerating diagnostic timelines. Furthermore, the robust and relatively simple operation of Ga-68 generators makes them ideal for integration into diverse healthcare settings, driving a substantial increase in PET scan availability and utilization globally. This democratizes access to critical diagnostic tools, fostering earlier disease detection and more personalized treatment strategies worldwide.
Global Gallium-68 Ga-68 Market Segmentation Analysis
Key Market Segments
By Application
- •Positron Emission Tomography
- •Radiopharmaceuticals
- •Research and Development
By End Use
- •Hospitals
- •Diagnostic Centers
- •Research Institutions
By Distribution Channel
- •Direct Sales
- •Distributors
- •Online Sales
By Formulation
- •Injectable
- •Lyophilized
- •Liquid
Segment Share By Application
Share, By Application, 2025 (%)
- Positron Emission Tomography
- Radiopharmaceuticals
- Research and Development
www.makdatainsights.com
Why is Positron Emission Tomography dominating the Global Gallium-68 Ga-68 Market?
Positron Emission Tomography or PET imaging currently holds the largest share within the application segment, primarily due to the widespread adoption of Gallium-68 radiopharmaceuticals for diagnostic purposes in oncology, cardiology, and neurology. Its superior imaging capabilities for early disease detection, precise localization, and treatment monitoring, particularly with agents like Ga-68 DOTATATE for neuroendocrine tumors and Ga-68 PSMA for prostate cancer, drive its significant market presence and continued growth.
How do End Use segments like Hospitals and Diagnostic Centers influence the Gallium-68 Ga-68 Market dynamics?
Hospitals and diagnostic centers collectively form the primary end use segments, directly reflecting the clinical demand for Ga-68 based radiopharmaceuticals. These institutions are critical for patient access to PET diagnostics and therapies, housing the necessary imaging equipment and medical professionals. Their continuous investment in nuclear medicine departments, expansion of diagnostic services, and increasing patient throughput directly correlate with the rising consumption of Gallium-68, making them pivotal to market expansion.
What role do Distribution Channels play in the accessibility of Gallium-68 Ga-68 products?
The distribution channel segment, encompassing direct sales, distributors, and online sales, is crucial for ensuring the timely and efficient delivery of these short lived radiopharmaceuticals to end users. Direct sales by manufacturers to major hospitals and research institutions offer specialized support and logistics, while distributors broaden reach to a wider network of diagnostic centers and smaller facilities. The efficiency of these channels is paramount given the radionuclide's half life, directly impacting product availability and market penetration.
Global Gallium-68 Ga-68 Market Regulatory and Policy Environment Analysis
The global Gallium 68 Ga 68 market operates within a highly regulated landscape, governed by stringent national and international policies. Regulatory bodies such as the US FDA, European Medicines Agency EMA, and Japan’s PMDA dictate comprehensive approval pathways for radiopharmaceuticals, emphasizing robust clinical data and adherence to Good Manufacturing Practices GMP. These agencies also oversee product lifecycle management, including post market surveillance. Distinct regulations exist for generator based radiolabeling at clinical sites versus commercially manufactured diagnostic kits, impacting market access and competition. Furthermore, national atomic energy commissions and health ministries impose strict licensing, handling, storage, and disposal requirements for radioactive materials, ensuring patient and environmental safety. Reimbursement policies, which vary significantly by country and healthcare system, profoundly influence market adoption, often linking coverage to demonstrated clinical efficacy and cost effectiveness. International harmonization efforts, though ongoing, still face regional specific requirements, necessitating tailored regulatory strategies for global market penetration. This multifaceted oversight ensures product quality, safety, and responsible use across diverse healthcare systems.
Which Emerging Technologies Are Driving New Trends in the Market?
The Gallium 68 market is being transformed by significant innovations. Advanced generator designs are enhancing elution yields and extending operational lifespans, improving accessibility for hospitals worldwide. Emerging chelator chemistries are enabling the labeling of novel targeting molecules, diversifying Ga 68’s diagnostic utility beyond prostate specific membrane antigen PSMA and somatostatin receptor SSTR imaging.
Automated synthesis modules are streamlining radiolabeling processes, reducing preparation times and ensuring greater consistency and purity of radiopharmaceuticals. Research is intensely focused on developing new Ga 68 labeled ligands for various oncological indications, including breast and lung cancers, and exploring applications in neurology and cardiology. Cyclotron based Ga 68 production offers a supplementary supply route, potentially mitigating generator related constraints. These technological advancements are pivotal for broadening Ga 68’s clinical adoption and driving market expansion.
Global Gallium-68 Ga-68 Market Regional Analysis
Global Gallium-68 Ga-68 Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
Dominant Region
North America · 38.2% share
North America stands out as the dominant region in the global Gallium 68 Ga 68 market. Securing a substantial 38.2% market share, the region's leadership is underpinned by several key factors. Advanced healthcare infrastructure, a high adoption rate of innovative diagnostic imaging technologies, and significant investment in nuclear medicine research and development contribute to its strong position. Furthermore, the presence of numerous specialized medical centers and a robust regulatory framework that supports the use of radiopharmaceuticals propel market growth. The region benefits from a well established network of radiopharmacies and expert medical professionals, ensuring efficient distribution and application of Gallium 68 Ga 68 based diagnostics across its vast healthcare landscape.
Fastest Growing Region
Asia Pacific · 14.2% CAGR
Asia Pacific is poised to be the fastest growing region in the Global Gallium-68 Ga-68 Market, exhibiting a remarkable CAGR of 14.2% from 2026 to 2035. This significant expansion is driven by several key factors. Increased healthcare expenditure across emerging economies is improving access to advanced medical treatments. A rapidly aging population in countries like Japan and South Korea fuels demand for diagnostic imaging, particularly for neuroendocrine tumors and prostate cancer where Ga-68 plays a crucial role. Furthermore, growing awareness and adoption of PET CT scans, coupled with continuous advancements in nuclear medicine infrastructure, are propelling market growth. Government initiatives supporting research and development in radiopharmaceuticals further solidify Asia Pacific's position as a high growth market.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical tensions, particularly involving major rare earth producers and consumers, significantly impact the gallium supply chain. China's dominance in gallium extraction and processing creates potential for export restrictions or price manipulation, directly affecting Ga-68 generator production and accessibility. Western efforts to diversify gallium sourcing, while mitigating long term risks, currently face infrastructure and investment hurdles, leading to short to medium term supply volatility. Regulatory changes regarding radiopharmaceutical production and transportation in various nations also shape market dynamics, favoring localized production or robust international logistics.
Macroeconomic conditions exert considerable influence. Inflationary pressures drive up manufacturing costs for Ga-68 generators and precursor materials, potentially increasing end user prices and impacting adoption rates in price sensitive regions. Fluctuations in research and development funding for novel radiopharmaceuticals, often tied to economic growth, can accelerate or slow market expansion. Healthcare expenditure trends, particularly in cancer diagnostics and personalized medicine, dictate demand for advanced imaging agents like Ga-68, with economic downturns potentially delaying widespread reimbursement and adoption.
Recent Developments
- March 2025
RadioMedix and NMS Healthcare announced a strategic partnership to expand the distribution network for their Ga-68 based radiopharmaceuticals across key European markets. This collaboration aims to streamline logistics and increase patient access to advanced diagnostic imaging agents.
- September 2024
ITG Isotope Technologies Garching successfully launched a new generation of Ga-68 generator designed for enhanced elution efficiency and longer shelf-life. This product innovation directly addresses the operational challenges faced by nuclear medicine departments in maintaining a consistent supply of Ga-68.
- July 2025
Advanced Accelerator Applications (a Novartis company) acquired GMP Laboratories, a leading manufacturer of sterile radiopharmaceutical precursors. This acquisition strengthens AAA's supply chain for critical components used in Ga-68 radiopharmaceutical production and expands their manufacturing footprint.
- November 2024
Curium announced a major strategic initiative to invest in the development of novel Ga-68 theranostic agents, moving beyond current diagnostic applications into therapeutic uses. This multi-year program will involve significant R&D expenditure and clinical trials to explore new treatment options for various cancers.
Key Players Analysis
Key players like Novartis and Advanced Accelerator Applications are pivotal, leveraging advanced radiopharmaceutical technologies for Ga-68 production. Curium and RadioMedix focus on expanding generator and dose availability, while Iochem and ITG Isotope Technologies Garching drive innovation in manufacturing. Strategic partnerships and research initiatives by these companies, including GMP Laboratories, are crucial for market growth, addressing the rising demand for PET imaging diagnostics globally.
List of Key Companies:
- Iochem
- Novartis
- Curium
- Elekta
- GMP Laboratories
- RadioMedix
- NMS Healthcare
- ITG Isotope Technologies Garching
- General Electric
- Advanced Accelerator Applications
- BristolMyers Squibb
- MediRadiant
- Lantheus Medical Imaging
- Eisai
- Siemens Healthineers
- Philips Healthcare
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 0.85 Billion |
| Forecast Value (2035) | USD 2.95 Billion |
| CAGR (2026-2035) | 14.2% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 2: Global Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 3: Global Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 4: Global Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 5: Global Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 7: North America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 8: North America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 9: North America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 10: North America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 12: Europe Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 13: Europe Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 14: Europe Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 15: Europe Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 17: Asia Pacific Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 18: Asia Pacific Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 19: Asia Pacific Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 20: Asia Pacific Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 22: Latin America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 23: Latin America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 24: Latin America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 25: Latin America Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 27: Middle East & Africa Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by End Use, 2020-2035
Table 28: Middle East & Africa Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035
Table 29: Middle East & Africa Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Formulation, 2020-2035
Table 30: Middle East & Africa Gallium-68 Ga-68 Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035